BEDFORD, Mass., Feb. 2, 2007 /PRNewswire-FirstCall/ -- Hologic, Inc. (NASDAQ: HOLX), a leading provider of state-of-the-art diagnostic and digital imaging systems directed towards women's health, today announced the amendment of the Rule 10b5-1 trading plan originally established by Glenn P. Muir, Executive Vice President and Chief Financial Officer, on January 31, 2006. As amended, the total number of shares expected to be sold by Mr. Muir in 2007 pursuant to the plan has been reduced from 110,000 to 80,000 shares. Under the plan, Mr. Muir will exercise stock options for 10,000 shares beginning on February 7, 2007 and continuing once each month through September 2007. A total of 80,000 shares are expected to be acquired upon exercise and sold for his account.
Mr. Muir's 10b5-1 trading plan is designed to enable him to diversify a portion of his Hologic equity interests in an orderly manner. The plan and the amendment were established by Mr. Muir while not in possession of any material non-public information and in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 and the Company's insider trading policy.
Rule 10b5-1 allows officers and directors to adopt written plans to sell shares under pre-arranged terms when they do not have material nonpublic information. The rule allows officers and directors adopting such plans to sell shares over a specified amount of time, at specific prices in the future, even if subsequent material and non-public information becomes available to them. Using these plans, officers and directors can gradually diversify their investment portfolios, can spread stock trades out over an extended period of time to reduce any significant market impact and can avoid concerns about whether they had material nonpublic information when they sold their stock. Sales of stock by Mr. Muir, pursuant to the terms of his plan, will be disclosed publicly through Form 144 and Form 4 filings with the Securities and Exchange Commission.
About Hologic Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of innovative imaging technology for digital radiography and breast imaging. Hologic's core business units are focused on mammography and breast biopsy, osteoporosis assessment, and mini C- arm and extremity MRI imaging for orthopedic applications. For more information visit www.hologic.com.
Director, Investor Relations
Tel: (781) 999-7377
SOURCE: Hologic, Inc.